| Date | Time | Source | Headline | Symbol | Company |
| 05/17/2024 | 3:00PM | iHub Newswire | FeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements | | |
| 03/14/2012 | 8:04PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 03/14/2012 | 8:03PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 03/14/2012 | 8:03PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 03/14/2012 | 7:30PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 03/14/2012 | 7:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 03/14/2012 | 6:47PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 03/14/2012 | 6:35PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 03/12/2012 | 5:37PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 03/08/2012 | 7:00PM | Business Wire | Data Show Gilead’s Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study | NASDAQ:GILD | Gilead Sciences Inc |
| 03/08/2012 | 3:12PM | Dow Jones News | WSJ BLOG/Health: Study of Popular HIV Drug Fuels Prevention Debate | NASDAQ:GILD | Gilead Sciences Inc |
| 03/08/2012 | 2:13PM | Dow Jones News | CORRECT(3/7): Gilead's 'Quad' HIV Drug Is Comparable To Atripla In Study | NASDAQ:GILD | Gilead Sciences Inc |
| 03/08/2012 | 9:40AM | Dow Jones News | WSJ BLOG/Health: Study of Popular HIV Drug Fuels Prevention Debate | NASDAQ:GILD | Gilead Sciences Inc |
| 03/07/2012 | 4:12PM | Dow Jones News | Gilead's 'Quad' HIV Drug Is Comparable To Atripla In Study | NASDAQ:GILD | Gilead Sciences Inc |
| 03/07/2012 | 3:00PM | Business Wire | Gilead’s Quad Single Tablet Regimen for HIV Non-Inferior to Atripla® in Pivotal Phase 3 Study | NASDAQ:GILD | Gilead Sciences Inc |
| 03/06/2012 | 4:35PM | Business Wire | Gilead Sciences Quad Study 102 Results Conference Call on Wednesday, March 7, 2012 | NASDAQ:GILD | Gilead Sciences Inc |
| 03/06/2012 | 4:30PM | Business Wire | Gilead Sciences to Present at the Barclays Capital 2012 Global Healthcare Conference on Tuesday, March 13 | NASDAQ:GILD | Gilead Sciences Inc |
| 03/05/2012 | 8:36PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 03/05/2012 | 8:36PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 02/29/2012 | 4:30PM | Business Wire | Gilead Sciences to Present at the Cowen & Company 32nd Annual Health Care Conference on Wednesday, March 7 | NASDAQ:GILD | Gilead Sciences Inc |
| 02/27/2012 | 6:00AM | Zacks | Actelion Gets Auxilium Drug Rights - Analyst Blog | NASDAQ:GILD | Gilead Sciences Inc |
| 02/24/2012 | 4:30PM | Business Wire | Gilead Sciences to Present at Two Upcoming Investor Conferences | NASDAQ:GILD | Gilead Sciences Inc |
| 02/24/2012 | 1:17PM | Zacks | Action Date for UTHR Candidate - Analyst Blog | NASDAQ:GILD | Gilead Sciences Inc |
| 02/23/2012 | 4:21PM | Edgar (US Regulatory) | Annual Report (10-K) | NASDAQ:GILD | Gilead Sciences Inc |
| 02/23/2012 | 3:37PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GILD | Gilead Sciences Inc |
| 02/21/2012 | 10:36AM | Zacks | Gilead's HCV Drug Suffers Setback - Analyst Blog | NASDAQ:GILD | Gilead Sciences Inc |
| 02/21/2012 | 9:31AM | PR Newswire (US) | Seven Summits Research Releases Comments on UPS, Hewlett-Packard, Gilead, Express Scripts and Chesapeake Energy | NASDAQ:GILD | Gilead Sciences Inc |
| 02/17/2012 | 2:16PM | Dow Jones News | 2nd UPDATE: Patients On Gilead's Hepatitis C Drug Relapse In Trial | NASDAQ:GILD | Gilead Sciences Inc |
| 02/17/2012 | 11:32AM | Dow Jones News | UPDATE: Patients On Gilead's Hepatitis C Drug Relapse In Trial | NASDAQ:GILD | Gilead Sciences Inc |
| 02/17/2012 | 10:00AM | Zacks | Gilead Remains Neutral - Analyst Blog | NASDAQ:GILD | Gilead Sciences Inc |